Consider This Before Taking a Position in Zimmer Biomet (ZBH)

Zimmer Biomet sank -1.3% this morning, compared to the S&P 500's day change of 0.0%. Today's losers may turn out to be tomorrow's winners, so be sure to check the stock's fundamentals before making an investment decision:

  • Zimmer Biomet has logged a 4.0% 52 week change, compared to 16.0% for the S&P 500

  • ZBH has an average analyst rating of hold and is -26.05% away from its mean target price of $150.14 per share

  • Its trailing earnings per share (EPS) is $2.4, which brings its trailing Price to Earnings (P/E) ratio to 46.3. The Health Care sector's average P/E ratio is 24.45

  • The company's forward earnings per share (EPS) is $8.04 and its forward P/E ratio is 13.8

  • The company has a Price to Book (P/B) ratio of 1.87 in contrast to the Health Care sector's average P/B ratio is 4.16

  • The current ratio is currently 1.9, which consists in its liquid assets divided by any liabilities due within in the next 12 months

  • ZBH has reported YOY quarterly earnings growth of 37.0% and gross profit margins of 0.7%

  • The company's free cash flow for the last fiscal year was $1.54 Billion and the average free cash flow growth rate is 0.0%

  • Zimmer Biomet's revenues have an average growth rate of 0.0% with operating expenses growing at -10.5%. The company's current operating margins stand at 17.7%

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.